Infectious Disease

Infants can quickly produce novel antibodies that protect against HIV.

Antiretroviral therapy use and viral suppression heavily impacted by issues such as poverty and race.

Some injection drug users with HIV and hepatitis C seem to have the same immune problems as the elderly.

Protease inhibitors can frequently lead to cardiovascular disease, diabetes, and obesity.

Engineering bacteria to deliver HIV-1 neutralizing antibodies at the site where the virus enters the body may offer a cost-effective barrier to HIV-1 transmission.

HIV-like virus eliminated from body with early administration of treatment.

Further research is needed for HIV to be treated by the CRISPR/Cas9 gene editing tool.

Protease inhibitors can lead to the development of cardiovascular disease, diabetes, and obesity in patients with HIV.

Harnessing the immune system may lead to an effective HIV vaccine strategy.

Greater education programming needed for patients at-risk for HIV infection.

There was a 210% increase in NTM occurrence in patients with COPD taking ICS.

“HIV isn’t the end of the world. HIV is actually just the beginning.”

PEPFAR saw a 33% decrease in funding for HIV/AIDS services.

Accuracy improved in point-of-care urine testing for the screening of tuberculosis in HIV patients.

Acute infection screening program for HIV shows promise.

Study hopes to overcome significant challenges in producing an HIV vaccine.

Denmark is close to eradicating HIV through a prevention approach.

Association found between persistent immune activation, arterial inflammation, and plaque development in HIV

The critical beginning stages of HIV have been found to be less symptomatic than previously thought.

Neutron crystallography improves insight about the enzyme HIV-1 protease.

Patients receiving same-day treatment for HIV were more likely to start antiretroviral therapy and had better viral suppression.

Potent broadly neutralizing antibody binds to HIV and causes a strong immune response.

Adherence to antiretroviral treatment negatively affected among patients with HIV who use drugs.

An HIV PrEP program would cost about $44 billion, but could prevent 21,500 new infections.

Current HIV criminalization laws may be unfairly biased due to assumptions about intent to transmit the virus in sexual activity.